Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | BAD | Q92934 | 1/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL54677 | 1.00 | CES2 (0.62) | CES2CES1MAOBCA1CA2 | |
| Hydrochloric Acid SCHEMBL27523727 | 0.97 | CES2 (0.59) | CES2CES1MAOBCA1CA2 | |
| Acetic Acid SCHEMBL28372390 | 0.95 | CES2 (0.56) | CES2CES1MAOBCA1CA2 | |
| Boric Acid SCHEMBL29051484 | 0.93 | MAOB (0.55) | CES2CES1MAOBCA1CA2 | |
| SCHEMBL7937485 | 0.93 | LTA4H (0.59) | CES2CES1MAOBCA1CA2 | |
| SCHEMBL4448294 | 0.93 | SMN1; SMN2 (0.64) | CES2CES1MAOBCA1CA2 | |
| Acetohydroxamic Acid SCHEMBL28835704 | 0.89 | MAOB (0.51) | CES2CES1MAOBCA1CA2 | |
| SCHEMBL3370005 | 0.87 | HPGD (0.79) | CES2CES1MAOBCA1CA2 | |
| SCHEMBL7938515 | 0.87 | KMT2A (0.79) | CES2CES1MAOBCA1CA2 | |
| SCHEMBL3138940 | 0.87 | HPGD (0.79) | CES2CES1MAOBPTGS1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674101-B2 | Nucleophilic fluorination of aromatic compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130251632-A1 | APOPTOSIS PET IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130149241-A1 | PEPTIDE RADIOTRACER COMPOSITIONS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-20130052132-A1 | Method for Producing Radioactively Labeled Polypeptide | ARKRAY, INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20120087863-A1 | Peptide Derivative and Use of the Same | ARKRAY, INC. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20110206605-A1 | Molecular Probe for Imaging of Pancreatic Islets and Use of the Same | KYOTO UNIVERSITY (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110196149-A1 | FLUORIDATION METHOD | GE HEALTHCARE LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110178302-A1 | NUCLEOPHILIC FLUORINATION OF AROMATIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-21 | — | — | US | disclosed |
| US-7935852-B2 | Fluoridation method | GE HEALTHCARE LIMITED (GB) | 2011-05-03 | — | — | US | disclosed |
| US-20110081663-A1 | Molecular Probe for Imaging of Pancreatic Islets and Use of the Same | KYOTO UNIVERSITY (JP) | 2011-04-07 | — | — | US | disclosed |
| US-7919579-B2 | Imaging and therapeutic targeting of prostate and bladder tissues | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090123381-A1 | IMAGING AND THERAPEUTIC TARGETING OF PROSTATE AND BLADDER TISSUES | US ARMY, SECRETARY OF THE ARMY | 2009-05-14 | — | — | US | disclosed |
| US-20070092441-A1 | Fluoridation method | GE HEALTHCARE LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070092441-A1 | Fluoridation method | FLNB, FLNA, ARFGEF1 | CES2 309/4885CES1 1352/4885MAOB 660/4885 |
| US-20110206605-A1 | Molecular Probe for Imaging of Pancreatic Islets and Use of the Same | IAPP, NGLY1, GPR119 | CES2 4040/4885CES1 1632/4885MAOB 4223/4885 |
| US-20120087863-A1 | Peptide Derivative and Use of the Same | VIP, IAPP, GLP1R | CES2 3993/4885CES1 3438/4885MAOB 3234/4885 |
| US-20130052132-A1 | Method for Producing Radioactively Labeled Polypeptide | XPNPEP2, ARGLU1, XPNPEP1 | CES2 2285/4885CES1 2904/4885MAOB 1545/4885 |
| US-20110196149-A1 | FLUORIDATION METHOD | FLNB, FLNA, ARFGEF1 | CES2 309/4885CES1 1352/4885MAOB 660/4885 |
| US-20130251632-A1 | APOPTOSIS PET IMAGING AGENTS | BAX, CASP3, PHOSPHO1 | CES2 1864/4885CES1 1492/4885MAOB 4327/4885 |
| US-20110178302-A1 | NUCLEOPHILIC FLUORINATION OF AROMATIC COMPOUNDS | SLC18A2, AFF4, SLC6A19 | CES2 1177/4885CES1 4597/4885MAOB 30/4885 |
| US-20130149241-A1 | PEPTIDE RADIOTRACER COMPOSITIONS | MET, GRPR, MEN1 | CES2 2771/4885CES1 2021/4885MAOB 4102/4885 |
| US-20090123381-A1 | IMAGING AND THERAPEUTIC TARGETING OF PROSTATE AND BLADDER TISSUES | ADM2, DAB2IP, ARG2 | CES2 3142/4885CES1 3453/4885MAOB 2197/4885 |
| US-20110081663-A1 | Molecular Probe for Imaging of Pancreatic Islets and Use of the Same | IAPP, GPR119, NPY1R | CES2 4439/4885CES1 1937/4885MAOB 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.